Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A, -- Ignore unavailable to you. Want to Upgrade?

To: Jibacoa who wrote (1233)	7/15/2005 4:22:10 PM
From: Jibacoa	Respond to of 3722

GENZ Also is making a new 52 wks. H as it is up for 3rd day on a roll with volume above 24.43M It has no intention on closing its July 14 upgap.<g> On July1 it completed the acquisition of Bone Care. The 2nd Q revenues were up 22% and earnings were up 30% to $0.57/shr. The EE for 2005 are around $2.17/shr vs. $1.82 in 2004 and for 2006 the EE are around $2.60/shr.<g> The stock was up 7.67% on volume above 11.28M bigcharts.marketwatch.com Bernard

To: Jibacoa who wrote (1233)	2/12/2008 10:30:00 AM
From: Jibacoa	Read Replies (1) \| Respond to of 3722

DYAX opened with an UG & is still up 25.56% on volume of 515,355 >4x its ADV bigcharts.marketwatch.com It announced today that they have entered into agreements in which SNF.L has been granted an exclusive worldwide license for the development and commercialization of its human monoclonal antibody DX-2240, as well as a nonexclusive license to DYAX’s antibody phage display technology. DYAX could receive $500M in license fees and milestone payments ,it will receive $25M in 2008 & is eligible to receive royalties based on commercial sales of DX-2240 and other antibodies developed. DX-2240 is a human monoclonal antibody that targets the Tie-1 receptor on tumor blood vessels and has potential in numerous oncology indications. The "analysts" have a target around $7.67 & it seems with some further good news it could get to the $10 level.<g> bigcharts.marketwatch.com Bernard